Ketamine's Psychedelic Effects Not Linked to Therapeutic Benefits in Alcohol Use Disorder Treatment

A study conducted by King's College London and the University of Exeter indicates that the psychedelic experiences associated with ketamine do not predict its therapeutic benefits for individuals undergoing treatment for alcohol use disorder. Published in the journal Addiction, the research challenges the theory that ketamine's efficacy in this context stems directly from its strong psychedelic properties, suggesting that other mechanisms may be responsible for its anti-relapse effects.

Study Findings

The investigation utilized data from the Ketamine for Reduction of Alcoholic Relapse (KARE) clinical trial. Dr. Will Lawn, lead author and Senior Lecturer at King's College London, noted that participants reported typical subjective effects of ketamine, such as altered reality, bodily dissociation, and warped time perception.

"These experiences did not correlate with positive therapeutic outcomes."

The study found no substantial evidence that the intensity of these psychoactive effects predicted a reduction in alcohol consumption or the percentage of days abstinent from alcohol over a six-month period. Participants who received three weekly intravenous ketamine infusions reported significant psychoactive experiences, which remained consistent across sessions, indicating no development of tolerance over the short dosing period.

Methodology and Participants

The KARE clinical trial involved 96 adult participants across two clinical research facilities in England. It was designed as a randomized, placebo-controlled study with a six-month follow-up. This research represents the largest investigation into the psychological mechanisms of ketamine in substance use disorder treatment to date. The University College London was also involved in the utilization of KARE trial data.

Alternative Mechanisms and Future Research

Given the lack of correlation with psychedelic effects, alternative hypotheses for ketamine's relapse prevention capabilities have been proposed. These include its potential to alter brain networks related to addiction or stimulate the formation of new neural connections.

Professor Celia Morgan, from the University of Exeter and lead of the KARE study, highlighted the ongoing public health challenge posed by alcohol use disorder and the necessity for diverse, effective treatment options.

"She emphasized the need for further research to investigate how changes in brain connection and function contribute to ketamine's therapeutic action and to optimize dosing strategies."

A larger follow-up clinical trial, named MORE-KARE, is currently recruiting participants with alcohol problems throughout the UK to expand on these findings.